Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned ( 1:1:1 ) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel , carboplatin , and mapatumumab ( 10 mg/kg or 30 mg/kg ) .